Keryx Biopharmaceuticals Appoints Two New Board Members
21 juin 2016 08h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, June 21, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21
14 juin 2016 08h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, June 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
28 avr. 2016 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
Company reported $6.8 million in first quarter total revenues, including $5.6 million of Auryxia™ (ferric citrate) net U.S. product sales2016 product sales and cash operating expense guidance...
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2016 Financial Results on Thursday, April 28, 2016
14 avr. 2016 08h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, April 14, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
01 avr. 2016 08h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease
29 mars 2016 06h30 HE
|
Keryx Biopharmaceuticals, Inc.
Registration trial demonstrated statistically significant differences versus placebo for the primary and all pre-specified secondary endpointsMajority of patients in the ferric citrate group (52...
Keryx Biopharmaceuticals to Present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7
01 mars 2016 08h30 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
25 févr. 2016 07h00 HE
|
Keryx Biopharmaceuticals, Inc.
Fourth quarter Auryxia net U.S. product sales of $4.8 million Keryx provides 2016 Auryxia net U.S. product sales guidance of $31 - $34 millionCompany on track to provide pivotal phase 3 data...
Keryx Biopharmaceuticals to Host Conference Call on Fourth Quarter and Year End 2015 Financial Results on Thursday, February 25, 2016
11 févr. 2016 08h00 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal...
Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
22 déc. 2015 16h05 HE
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...